Endovascular therapy for hemodialysis patients with atrial fibrillation and cerebral thromboembolism: A case series

Author:

Kamijo Masafumi1,Hayashi Waka1ORCID,Otsuka Emiko1,Obata Yoko2,Sahara Noriyuki3,Takemoto Koichiro4,Sakamoto Seisaburo4,Ueki Yukitaka5,Nishino Tomoya6

Affiliation:

1. Department of Nephrology, Sasebo Chuo Hospital, Sasebo, Japan

2. Medical Education Development Center, Nagasaki University Hospital, Nagasaki, Japan

3. Department of Cerebrovascular Medicine, Sasebo Chuo Hospital, Sasebo, Japan

4. Department of Neurosurgery, Sasebo Chuo Hospital, Sasebo, Japan

5. Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan

6. Department of Nephrology, Nagasaki University Hospital, Nagasaki, Japan

Abstract

Introduction: Hemodialysis patients with atrial fibrillation are at high risk for stroke. Intravenous recombinant tissue plasminogen activator is considered for acute ischemic stroke. However, recombinant tissue plasminogen activator therapy is contraindicated for some hemodialysis patients with atrial fibrillation. These patients and those who have received recombinant tissue plasminogen activator therapy without blood flow recovery are candidates for endovascular therapy. Methods and results: Three hemodialysis patients with atrial fibrillation received endovascular therapy for acute cerebral infarction. Cerebrovascular incident occurred during or after hemodialysis in two of these patients. All three patients achieved successful recanalization after endovascular therapy. Conclusion: In this series, endovascular therapy showed good results without complications. More cases should be investigated to obtain more evidence of successful endovascular therapy for hemodialysis patients.

Publisher

SAGE Publications

Subject

Biomedical Engineering,Biomaterials,General Medicine,Medicine (miscellaneous),Bioengineering

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3